UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2026 (Report No. 3)
Commission File Number: 001-40753
ICECURE
MEDICAL LTD.
(Translation of registrant’s name into
English)
7 Ha’Eshel St., PO Box 3163
Caesarea, 3079504 Israel
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
CONTENTS
On
November 9, 2026, IceCure Medical Ltd. (the “Company”) issued a press release titled “IceCure Granted New Patent in
China for Its Cryogenic System Connector, Expanding Its Global IP Portfolio”, a copy of which is furnished as Exhibit 99.1 to this
Report of Foreign Private Issuer on Form 6-K.
This
Report of Foreign Private Issuer on Form6-Kis incorporated by reference into the Company’s Registration Statements on Form F-3
(File Nos. 333-297030, 333-290046
and 333-258660) and
Form S-8 (333-298361, 333-270982, 333-264578,
333-262620 and 333-281587),
filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer
on Form6-Kis submitted, to the extent not superseded by documents or reports subsequently filed or furnished
EXHIBIT INDEX
| Exhibit No. |
|
|
| 99.1 |
|
Press Release issued by IceCure Medical Ltd., dated November 9, 2026, titled “IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP Portfolio.” |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
IceCure Medical Ltd. |
| |
|
|
| Date: November 9, 2026 |
By: |
/s/ Eyal Shamir |
| |
|
Name: |
Eyal Shamir |
| |
|
Title: |
Chief Executive Officer |
Exhibit 99.1
IceCure Granted New Patent in China for Its Cryogenic System Connector,
Expanding Its Global IP Portfolio
Newly Granted Patent Adds to IceCure’s Portfolio of 42 Patents
Across the U.S., Europe and Asia, Further Strengthening Its Intellectual Property Protection in Key International Markets
CAESAREA, Israel, November 9, 2026 /PRNewswire/ -- IceCure Medical
Ltd. (Nasdaq: ICCM) (“IceCure,” “IceCure Medical” or the “Company”), a developer of minimally-invasive cryoablation
technology that destroys tumors by freezing as an option to surgical tumor removal, announced today that the China National Intellectual
Property Administration (“CNIPA”) has granted the Company a new patent in China, covering a connector used in its cryogenic
technology platform, further expanding IceCure’s global intellectual property portfolio and strengthening the protection of its proprietary
cryogenic technologies in key international markets.
The patented connector is part of IceCure’s cryogenic technology platform,
and the patent grant follows a recent regulatory milestone for the Company in China. In September 2026, IceCure received approval from
China’s National Medical Products Administration to market ProSense® and its associated cryoprobes in China.
IceCure’s intellectual property portfolio contains 42 patents across
the United States, Europe, Great Britain, China and Japan.
IceCure’s intellectual property portfolio covers its technological
platform and proprietary technologies, including innovations intended for incorporation into its current and future products. The Company
continues to protect and expand its intellectual property portfolio across international markets, supporting its long-term technology
strategy and protecting its proprietary innovations.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets
advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, as a safe
and effective minimally invasive option to surgical tumor removal, with the primary focus areas being breast, kidney, bone and lung cancer.
The Company’s flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including
in the U.S., Europe, and Asia.
ProSense® cryoablation became the first-and-only
medical device cleared by the FDA for the local treatment of breast cancer in patients aged 70 years and older with biologically low-risk
tumors ≤1.5 cm in size who are treated with adjuvant endocrine therapy, including patients who are not eligible for surgery.
Investor Relations:
Meir Peleg, CFO
investors@icecure-medical.com
+1-888-902-5716
Forward Looking Statements
This press release contains “forward-looking statements”
within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are
based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by
the use of forward-looking terms such as “believe,” “expect,” “may,” “should,” “could,”
“seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable
terms. For example, the Company is using forward-looking statements when it discusses the belief that the CNIPA patent grant expands the
Company’s global intellectual property portfolio and strengthens the protection of its proprietary cryogenic technologies in key
international markets; the Company’s potential future intellectual property portfolio and its long-term growth strategy and objectives.
Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in
these forward-looking statements include, among others: the Company’s planned level of revenues and capital expenditures; the Company’s
available cash and its ability to obtain additional funding; the Company’s ability to market and sell its products; legal and regulatory
developments in the United States and other countries; the Company’s ability to maintain its relationships with suppliers, distributors
and other partners; the Company’s ability to maintain or protect the validity of its patents and other intellectual property; the Company’s
ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East,
specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company’s Annual Report on Form 20-F for
the year ended December 31, 2025 filed with the SEC on March 17, 2026, and other documents filed with or furnished to the SEC which are
available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes
after the date of this release, except as required by law.
